AMENDMENT NO. 2 TO WATSON PHARMACEUTICALS, INC. KEY EMPLOYEE AGREEMENT
Exhibit 10.30
This Amendment No. 2 to Key Employee Agreement (this “Amendment”) by and between ▇▇▇▇▇ ▇▇▇▇,
Ph.D. (“Executive”) and ▇▇▇▇▇▇ Pharmaceuticals, Inc. (the “Company”), a Nevada corporation is
entered into as of February 21, 2008 (the “Effective Date”), and, to the extent provided herein,
amends that certain Key Employee Agreement between Executive and the Company dated as of June 30,
1999, as amended by that certain Amendment No. 1 to ▇▇▇▇▇▇ Pharmaceuticals, Inc. Key Employee
Agreement dated November 15, 2000 (the “Agreement”).
Whereas, the Company and Executive have entered into the Agreement, pursuant to which
Executive serves as Senior Vice President, Scientific Affairs of the Company; and
Whereas, the Company and Executive desire to amend the Agreement to the extent
provided herein.
Now, Therefore, in consideration of the mutual promises and covenants contained
herein, it is hereby agreed by and between the parties hereto as follows:
1. Section 409A. New Section 10.12 shall be inserted immediately after Section 10.11 of the
Agreement to read in its entirety as follows:
“This Agreement is intended to be interpreted and construed in a manner that
does not cause Executive to incur federal tax liability under Section 409A of the
Code.”
2. Exhibit A. Exhibit A of the Agreement shall be deleted and replaced in its
entirety with the Exhibit A attached to this Amendment.
3. Exhibit B. Exhibit B of the Agreement shall be deleted and replaced in its
entirety with the Exhibit B attached to this Amendment.
4. No Other Changes. Except as provided in this Amendment, the Agreement shall
remain in full force and effect.
5. Definitions. Unless otherwise defined herein, all capitalized terms shall have the
meaning as set forth in the Agreement.
(Signature Page Follows)
In Witness Whereof, the parties have executed this Agreement effective as of the
Effective Date above written.
| ▇▇▇▇▇▇ Pharmaceuticals, Inc. |
||||
| By: | ||||
| Name: | ||||
| Title: | ||||
| Executive: |
||||
| Name: ▇▇▇▇▇ ▇▇▇▇ |
||||
2
Exhibit A
COMPENSATION AND SEVERANCE TERMS SCHEDULE
1. BASE SALARY
For services to be rendered under this Agreement, Executive shall receive an annual base
salary at an annualized rate of $343,121.00, payable in accordance with the Company’s standard
payroll practices, and subject to increases as set forth in this Agreement.
2. BONUS
Executive’s annual bonus, if granted, shall be at an annual target level of at least 35% of
Executive’s then current base salary, and shall be subject to any bonus programs or bonus plans
generally applicable to other senior executives of the Company.
3. [INTENTIONALLY OMITTED]
4. SEVERANCE BENEFITS
4.1 Executive’s Termination of Employment. Notwithstanding anything to the contrary in the
Agreement, if the Company terminates Executive’s employment or if Executive terminates his
employment voluntarily for any or no reason at any time during the Employment Term (in either case
other than in a Change in Control Termination) such termination shall be deemed a resignation for
Good Reason and the Company shall provide to Executive, within thirty (30) days after the Effective
Date of the Release attached hereto as Exhibit B (as “Effective Date” is defined in the Release) or
such later date as may be required under Section 4.4, as the only severance compensation and
benefits all of the following:
(a) A lump sum severance payment, subject to standard withholdings or deductions, in an amount
equal to the sum of: (i) twenty-four (24) months of Executive’s then base salary; (ii) two times
Executive’s target bonus to be earned for the year in which termination occurs or two times the
bonus amount paid to the Executive in the prior year, which is greater; and (iii) Executive’s
prorated bonus (based on Executive’s target bonus amount) for the year in which the termination
occurs.
(b) Continued group health insurance benefits at the same rate generally charged to Company
employees for Executive and his current spouse (as of the Effective Date) (“Spouse”) for the rest
of their lives (“Coverage Period”); provided, however, that once Executive or his Spouse becomes
Medicare eligible, the Company shall coordinate that individual’s medical insurance benefits with
Medicare, and such benefits shall be secondary to Medicare. During the Coverage Period, the
Company, at its election, shall either (i) arrange commercial medical coverage for Executive and
his Spouse (which is (x) comparable to the medical benefits provided to Executive and his Spouse
immediately prior to commencement of such commercial medical care coverage, (y) subject to change
if such coverage is no longer available, and (z) mutually agreeable to the Company and Executive),
or (ii) provide Executive and his Spouse continued coverage under the Company’s medical insurance
plan. Executive
shall be responsible for any personal income taxes payable in connection with the receipt of
the benefits described in this paragraph 4.1(b).
(c) Outplacement services for one year with a nationally recognized service selected by the
Company.
4.2 Executive’s Resignation For Good Reason. If Executive terminates his employment with the
Company for Good Reason, the Company shall provide to Executive, within thirty (30) days after the
Effective Date of the Release attached hereto as Exhibit B (as “Effective Date” is defined in the
Release), as the only severance compensation and benefits, the same severance compensation and
benefits provided in Section 4.1 hereof.
4.3 Change of Control Termination. In the event of a Change of Control Termination, the
Company shall provide to Executive, within thirty (30) days after the Effective Date of the Release
attached hereto as Exhibit B (as “Effective Date” is defined in the Release) or such later date as
may be required pursuant to Section 4.4, as the only severance compensation and benefits: (a) the
same severance compensation and benefits provided in Section 4.1 hereof and, (b) any unvested
Options and restricted stock awards held by Executive shall have their vesting accelerated in full
so as to become one hundred percent (100%) vested and, if applicable, immediately exercisable in
full as of the date of such termination.
4.4 Delayed Payments. Notwithstanding anything in this Section 4 to the contrary, if the
Company determines in good faith that any payment or benefit under this Section 4, that is payable
to Executive on account of a termination of employment with the Company, constitutes a “deferral of
compensation” under Code Section 409A (as set forth in IRS Notice 2005-1, or the Final Treasury
Regulations), and that Executive is a “specified employee” within the meaning of Code Section
409A(a)(2)(B)(i), then the Company shall delay commencement of any such payment or benefit until
six months after the Effective Date which constitutes a “separation from Service” (as such term is
used in Code Section 409A) or, if later, the Effective Date of the Release attached hereto as
Exhibit B (as “Effective Date” is defined in the Release) (the “409A Suspension Period”). With
respect to any benefits to be provided by the Company (such as continued medical benefits, if any),
if necessary in order to avoid any additional tax or interest under Code Section 409A, Executive
shall pay for such benefits directly during the 409A Suspension Period. Within 15 calendar days
after the end of the 409A Suspension Period, the Company shall pay to Executive a lump sum payment
in cash equal to any payments and benefits (including interest on any such payments and benefits,
at an interest rate equal to the 120-month rolling average yield to maturity of the index called
the “▇▇▇▇▇▇▇ ▇▇▇▇▇ U.S. Corporate, A Rated, 15+ Years Index” as of December 31 of the year
preceding the year of termination, for the 409A Suspension Period) that the Company would otherwise
have been required to provide under this Section 4 but for the imposition of the 409A Suspension
Period. Thereafter, Executive shall receive any remaining payments and benefits due under this
Section 4 in accordance with the terms of this Section 4 (as if there had not been any suspension
period). The provisions of this paragraph shall apply only to the minimum extent required to avoid
Executive’s incurrence of any additional tax or interest under Code Section 409A.
2
Exhibit B
RELEASE AGREEMENT
I understand that my position with ▇▇▇▇▇▇ Pharmaceuticals, Inc. (the “Company”) terminated
effective (the “Separation Date”). The Company has agreed that if I choose
to sign this Release, the Company will, within thirty (30) days after the Effective Date of this
Release or such later date as may be required by Internal Revenue Code Section 409A, pay me certain
severance benefits (minus the standard withholdings and deductions) pursuant to the terms of the
Key Employee Agreement entered into as of June 30, 1999, between myself and the Company, as amended
from time to time (the “Agreement”), and any agreements incorporated therein by reference. I
understand that I am not entitled to such severance benefits unless I sign this Release. I further
understand that, regardless of whether I sign this Release, the Company will pay me all of my
accrued base salary and paid time off through the Separation Date, to which I am entitled by law.
As a material inducement for the Company to enter into the Agreement, and in exchange for the
performance of the Company’s obligations under the Agreement provided for therein, I knowingly and
voluntarily waive and release all rights and claims, known and unknown, which I may have against
the Company and/or any of the Company’s related or affiliated entities or successors, or any of
their current or former officers, directors, managers, employees, agents, insurance carriers,
auditors, accountants, attorneys or representatives, including any and all charges, complaints,
claims, liabilities, obligations, promises, agreements, contracts, controversies, damages, actions,
causes of action, suits, rights, demands, costs, losses, debts and expenses of any kind. This
includes, but is not limited to, claims for employment discrimination, harassment, wrongful
termination, constructive termination, violation of public policy, breach of any express or implied
contract, breach of any implied covenant, fraud, intentional or negligent misrepresentation,
emotional distress, defamation, or any other claims relating to my relationship with the Company.
This also includes a release of any claims under any federal, state or local laws or regulations,
including, but not limited to: (1) Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000(e)
et seq. (race, color, religion, sex, and national origin discrimination); (2) the Age
Discrimination in Employment Act, as amended, 29 U.S.C. § 621 et seq. (the “ADEA”) (age
discrimination); (3) Section 1981 of the Civil Rights Act of 1866, 42 U.S.C. 1981 (race
discrimination); (4) the Equal Pay Act of 1963, 29 U.S.C. § 206 (equal pay); (5) the Fair Labor
Standards Act, 29 U.S.C. § 201, et seq. (wage and hour matters, including overtime pay); (6) COBRA;
(7) Executive Order 11141 (age discrimination); (8) Section 503 of the Rehabilitation Act of 1973,
29 U.S.C. § 701, et seq. (disability discrimination); (9) the Employee Retirement Income Security
Act of 1974, as amended, 29 U.S.C. § 1001, et seq. (employee benefits); (10) Title I of the
Americans with Disabilities Act (disability discrimination); and (11) any applicable state law
counterpart of any of the foregoing, including, without limitation, including the California Fair
Employment and Housing Act, the California Family Rights Act, claims for wages under the California
Labor Code. Notwithstanding the generality of the foregoing, I do not release (i) claims for
unemployment compensation or any state disability insurance benefits pursuant to the terms of
applicable state law; (ii) claims to continued participation in certain of the Company’s group
benefit plans pursuant to the terms and conditions of COBRA; (iii) claims to any benefit
entitlements vested as the date of separation of my employment pursuant to written terms of any
employee benefit plan of the Company or any affiliate or subsidiary of the Company; (iv) claims to
any equity awards which continue to vest following the separation of my employment, pursuant to the
written terms of the applicable equity compensation plan, the agreements evidencing such awards and
the Agreement; (v) my right to bring to the attention of the Equal Employment Opportunity
Commission claims of discrimination; provided, however, that I do release my right to secure any
damages for alleged discriminatory treatment; and (vi) my right under applicable law and the
Company’s D&O policy to seek indemnity for acts committed, or omissions, within the course and
scope of my employment duties. I ACKNOWLEDGE THAT I HAVE
BEEN ADVISED OF AND AM FAMILIAR WITH THE PROVISIONS
OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH
PROVIDES AS FOLLOWS: “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW
OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM
OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” BEING AWARE OF SAID
CODE SECTION, I HEREBY EXPRESSLY WAIVE ANY RIGHTS I MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER
STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
If I am forty (40) years of age or older as of the Separation Date, I acknowledge that I am
knowingly and voluntarily waiving and releasing any rights I may have under the federal Age
Discrimination in Employment Act of 1967, as amended (“ADEA”). I also acknowledge that this
paragraph, and this Release, are written in a manner calculated to be understood by me, and the
consideration given for the waiver in the above paragraph is in addition to anything of value to
which I was already entitled. I have been advised by this writing, as required by the ADEA that:
(a) my waiver and release do not apply to any claims that may arise after my signing of this
Release; (b) I should consult with an attorney prior to executing this Release; (c) I have
twenty-one (21) days (forty-five (45) days in the event of a group termination) within which to
consider this Release (although I may choose to voluntarily execute this Release earlier); (d) I
have seven (7) days following the execution of this release to revoke the Release; and (e) this
Release will not be effective until the eighth day after this Release has been signed both by me
and by the Company (“Effective Date”).
I acknowledge that I remain bound by the Employee Proprietary Information and Invention Agreement
which I signed in connection with my employment (“Invention Agreement”) and that the provisions of
the Invention Agreement shall remain in full force and effect. In accordance with my existing and
continuing obligations under the Invention Agreement, I have returned to the Company all materials
required to be returned pursuant to the Invention Agreement, as well as any other Company property
in my possession. In consideration for the severance benefits I am receiving hereunder, I agree
that I will reasonably cooperate with the Company after the Separation Date to assure the smooth
transition of pending matters and to answer questions which may arise from time to time regarding
my former duties and responsibilities. Effective as of the Separation Date, I resign any and all
offices and directorships with the Company and any of its affiliates except as otherwise provided
in the Agreement, and will execute all documents reasonably requested by the Company or its
affiliates to effectuate such resignations. Further, I agree that I will not hereafter disparage
the Company or any of the Releasees, either orally or in writing, to any person or entity. The
Company agrees that its officers and directors will not disparage me, either orally or in writing,
to any person or entity.
| Agreed: |
||||
| Date | ▇▇▇▇▇ ▇. ▇▇▇▇ | |||
| Date | ▇▇▇▇▇▇ PHARMACEUTICALS, INC. | |||
2